Is screening for osteoporosis worthwhile?

K Walker-Bone, D M Reid, C Cooper

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Osteoporosis is a common condition, which is recognised by the occurrence of fragility fractures and leads to considerable mortality and morbidity with huge financial implications world-wide. Based on predicted demographic changes, the implications of this disease are set to increasingly affect the healthcare budgets of all nations.

The determinants of fracture are skeletal factors, such as peak bone mass, the rate of bone loss and extra-skeletal factors, which include trauma and the response to that trauma. Some of these factors are genetically determined, but several have environmental origins, which could, theoretically, be manipulated.

There are two potential means whereby osteoporotic fractures might be prevented. Measures could be targeted at the entire population, with the aim of shifting the distribution of bone mass in a beneficial direction, through modifying the behaviour of all individuals. The alternative is a high risk approach, whereby intervention is targeted only at those considered to have the greatest risk of future fracture. Mass bone density screening falls into the second approach. Bone density is a good predictor of future fracture risk, and cost-effectiveness analyses of the high risk approach suggest economic benefits of policies targeting pharmacological treatment to those individuals at highest risk.

However, there are important concerns about the levels of compliance achievable with such therapeutic interventions, the balance of risks and benefits for some of these interventions (for example, hormone replacement therapy), and the outcome when treatment is discontinued. On current evidence, it is certainly not appropriate to target hormone replacement therapy for women at the menopause on the basis of a bone density screening programme. However, newer bone-specific agents are being developed which might be administered at later ages, closer to the time when fracture incidence rates rise steeply. Bone densitometry has been shown to predict fractures even in the elderly, and high risk strategies for the targeting of such agents (for example, the bisphosphonates or selective oestrogen receptor modulators) will remain important research issues for the future.

Original languageEnglish
Pages (from-to)915-927
Number of pages13
JournalBritish Medical Bulletin
Volume54
Publication statusPublished - 1998

Keywords

  • BONE-MINERAL DENSITY
  • HIP-FRACTURES
  • VERTEBRAL DEFORMITIES
  • POSTMENOPAUSAL WOMEN
  • PHYSICAL-ACTIVITY
  • CALCIUM
  • MASS
  • MANAGEMENT
  • POPULATION
  • IMPACT

Cite this

Walker-Bone, K., Reid, D. M., & Cooper, C. (1998). Is screening for osteoporosis worthwhile? British Medical Bulletin, 54, 915-927.

Is screening for osteoporosis worthwhile? / Walker-Bone, K ; Reid, D M ; Cooper, C .

In: British Medical Bulletin, Vol. 54, 1998, p. 915-927.

Research output: Contribution to journalArticle

Walker-Bone, K, Reid, DM & Cooper, C 1998, 'Is screening for osteoporosis worthwhile?', British Medical Bulletin, vol. 54, pp. 915-927.
Walker-Bone K, Reid DM, Cooper C. Is screening for osteoporosis worthwhile? British Medical Bulletin. 1998;54:915-927.
Walker-Bone, K ; Reid, D M ; Cooper, C . / Is screening for osteoporosis worthwhile?. In: British Medical Bulletin. 1998 ; Vol. 54. pp. 915-927.
@article{0854da34a70b4921bac73302cdcf81cd,
title = "Is screening for osteoporosis worthwhile?",
abstract = "Osteoporosis is a common condition, which is recognised by the occurrence of fragility fractures and leads to considerable mortality and morbidity with huge financial implications world-wide. Based on predicted demographic changes, the implications of this disease are set to increasingly affect the healthcare budgets of all nations.The determinants of fracture are skeletal factors, such as peak bone mass, the rate of bone loss and extra-skeletal factors, which include trauma and the response to that trauma. Some of these factors are genetically determined, but several have environmental origins, which could, theoretically, be manipulated.There are two potential means whereby osteoporotic fractures might be prevented. Measures could be targeted at the entire population, with the aim of shifting the distribution of bone mass in a beneficial direction, through modifying the behaviour of all individuals. The alternative is a high risk approach, whereby intervention is targeted only at those considered to have the greatest risk of future fracture. Mass bone density screening falls into the second approach. Bone density is a good predictor of future fracture risk, and cost-effectiveness analyses of the high risk approach suggest economic benefits of policies targeting pharmacological treatment to those individuals at highest risk.However, there are important concerns about the levels of compliance achievable with such therapeutic interventions, the balance of risks and benefits for some of these interventions (for example, hormone replacement therapy), and the outcome when treatment is discontinued. On current evidence, it is certainly not appropriate to target hormone replacement therapy for women at the menopause on the basis of a bone density screening programme. However, newer bone-specific agents are being developed which might be administered at later ages, closer to the time when fracture incidence rates rise steeply. Bone densitometry has been shown to predict fractures even in the elderly, and high risk strategies for the targeting of such agents (for example, the bisphosphonates or selective oestrogen receptor modulators) will remain important research issues for the future.",
keywords = "BONE-MINERAL DENSITY, HIP-FRACTURES, VERTEBRAL DEFORMITIES, POSTMENOPAUSAL WOMEN, PHYSICAL-ACTIVITY, CALCIUM, MASS, MANAGEMENT, POPULATION, IMPACT",
author = "K Walker-Bone and Reid, {D M} and C Cooper",
year = "1998",
language = "English",
volume = "54",
pages = "915--927",
journal = "British Medical Bulletin",
issn = "0007-1420",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Is screening for osteoporosis worthwhile?

AU - Walker-Bone, K

AU - Reid, D M

AU - Cooper, C

PY - 1998

Y1 - 1998

N2 - Osteoporosis is a common condition, which is recognised by the occurrence of fragility fractures and leads to considerable mortality and morbidity with huge financial implications world-wide. Based on predicted demographic changes, the implications of this disease are set to increasingly affect the healthcare budgets of all nations.The determinants of fracture are skeletal factors, such as peak bone mass, the rate of bone loss and extra-skeletal factors, which include trauma and the response to that trauma. Some of these factors are genetically determined, but several have environmental origins, which could, theoretically, be manipulated.There are two potential means whereby osteoporotic fractures might be prevented. Measures could be targeted at the entire population, with the aim of shifting the distribution of bone mass in a beneficial direction, through modifying the behaviour of all individuals. The alternative is a high risk approach, whereby intervention is targeted only at those considered to have the greatest risk of future fracture. Mass bone density screening falls into the second approach. Bone density is a good predictor of future fracture risk, and cost-effectiveness analyses of the high risk approach suggest economic benefits of policies targeting pharmacological treatment to those individuals at highest risk.However, there are important concerns about the levels of compliance achievable with such therapeutic interventions, the balance of risks and benefits for some of these interventions (for example, hormone replacement therapy), and the outcome when treatment is discontinued. On current evidence, it is certainly not appropriate to target hormone replacement therapy for women at the menopause on the basis of a bone density screening programme. However, newer bone-specific agents are being developed which might be administered at later ages, closer to the time when fracture incidence rates rise steeply. Bone densitometry has been shown to predict fractures even in the elderly, and high risk strategies for the targeting of such agents (for example, the bisphosphonates or selective oestrogen receptor modulators) will remain important research issues for the future.

AB - Osteoporosis is a common condition, which is recognised by the occurrence of fragility fractures and leads to considerable mortality and morbidity with huge financial implications world-wide. Based on predicted demographic changes, the implications of this disease are set to increasingly affect the healthcare budgets of all nations.The determinants of fracture are skeletal factors, such as peak bone mass, the rate of bone loss and extra-skeletal factors, which include trauma and the response to that trauma. Some of these factors are genetically determined, but several have environmental origins, which could, theoretically, be manipulated.There are two potential means whereby osteoporotic fractures might be prevented. Measures could be targeted at the entire population, with the aim of shifting the distribution of bone mass in a beneficial direction, through modifying the behaviour of all individuals. The alternative is a high risk approach, whereby intervention is targeted only at those considered to have the greatest risk of future fracture. Mass bone density screening falls into the second approach. Bone density is a good predictor of future fracture risk, and cost-effectiveness analyses of the high risk approach suggest economic benefits of policies targeting pharmacological treatment to those individuals at highest risk.However, there are important concerns about the levels of compliance achievable with such therapeutic interventions, the balance of risks and benefits for some of these interventions (for example, hormone replacement therapy), and the outcome when treatment is discontinued. On current evidence, it is certainly not appropriate to target hormone replacement therapy for women at the menopause on the basis of a bone density screening programme. However, newer bone-specific agents are being developed which might be administered at later ages, closer to the time when fracture incidence rates rise steeply. Bone densitometry has been shown to predict fractures even in the elderly, and high risk strategies for the targeting of such agents (for example, the bisphosphonates or selective oestrogen receptor modulators) will remain important research issues for the future.

KW - BONE-MINERAL DENSITY

KW - HIP-FRACTURES

KW - VERTEBRAL DEFORMITIES

KW - POSTMENOPAUSAL WOMEN

KW - PHYSICAL-ACTIVITY

KW - CALCIUM

KW - MASS

KW - MANAGEMENT

KW - POPULATION

KW - IMPACT

M3 - Article

VL - 54

SP - 915

EP - 927

JO - British Medical Bulletin

JF - British Medical Bulletin

SN - 0007-1420

ER -